The University of Pennsylvania, in collaboration with Lincoln University, Salus University, Temple University and the University of Pittsburgh, will receive $4.6 million to investigate the genetic and environmental determinants of Age-related Macular Degeneration (AMD), the leading cause of visual impairment in Pennsylvania. An intervention will be conducted to test the effectiveness of home- vs. office-based rehabilitation in African Americans with visual impairment. Wills Eye Health System, in partnership with Thomas Jefferson University and Temple University School of Medicine, will receive $3.6 million to study ways to reduce racial disparities in vision loss from diabetic retinopathy, a major cause of blindness. Researchers will test innovative interventions to encourage African Americans with diabetes to obtain recommended eye examinations. Despite the fact that annual dilated eye exams are known to reduce the risk of vision loss in people with diabetes, only 50 percent of older diabetics currently follow this recommendation. Drexel University, in association with Cheyney University, Inovio Biomedical Corporation and the University of Pennsylvania, will receive $2.8 million to conduct pre-clinical studies to test the safety and effect on the immune system of a vaccine that is designed to treat persons who are chronically infected with the hepatitis C virus (HCV) and have not responded to currently available therapies. Persons with chronic HCV infection face an increased risk of developing hepatocellular cancer, a difficult-to-treat cancer with a poor prognosis. Researchers expect that developing a vaccine to better treat HCV will ultimately lead to a reduction in hepatocellular cancer. Thomas Jefferson University, collaborating with Cheyney University, Fox Chase Cancer Center, Lincoln University, St. Joseph's University and the University of Pittsburgh, will receive $4.5 million to study new vaccine strategies for treating colorectal cancer, the second leading cause of cancer deaths in Pennsylvania. The research will include studies to encourage participation in cancer vaccine trials and a clinical trial to evaluate the safety and effect on the immune system of a guanylyl cyclase C (GCC)-based vaccine for treating colon cancer patients.  The University of Pennsylvania, working in concert with Fox Chase Cancer Center and Lincoln University, will receive $4.6 million to develop and test cancer vaccines and therapies to boost the immune system's ability to attack cancer cells. If successful, these strategies will prolong survival and reduce mortality in patients with ovarian and lung cancers. Together, these cancers account for approximately 30 percent of all cancer deaths in Pennsylvania.

These grants are awarded as part of the Commonwealth Universal Research Enhancement Program (CURE), which supports clinical, health services and biomedical research. 

SOURCE Pennsylvania Department of Health